BowHead Health Integrated Blockchain Medical Device Launches Second Phase of Token Sale
Bowhead Health is developing a medical device supported by cryptography that allows people to monitor and respond to their health data from the comfort of their own home. The company is named after the world’s longest living mammal and aims to positively impact human longevity.
Health data is arguably the most valuable information resource stored on the planet. It is sought after by research institutions and vital in the development of medical technology, yet in general, patients are not compensated for their own contributions to it nor are they guaranteed security from this highly personal information being shared with third parties. Bowhead Health is addressing these shortcomings by developing a health platform that compensates individuals who provide anonymized health data to the Bowhead blockchain. Individuals receive 70% of the funds paid by research institutions in exchange for health data, with Bowhead token holders receiving the remaining 30% of the funds.
“Not only is the application of this platform valuable for the developed world in people’s homes and offices but we also see it being used in a kiosk format for an entire rural community in the developing world where medical care is not readily available,” added Dr. Francisco Diaz-Mitoma. We are thrilled to be operating at the intersection of cryptography, biochemistry, hardware and software to bring our Bowhead vision to life,” says Dr. Mehta.
The startup intends to launch in two phases, with home test kits being shipped to a lab by fall 2017 and realtime diagnostic and dispenser devices by winter 2018. Bowhead Health is the first of its kind in using a medical device paired to a Blockchain.
The company was co-founded 18 months ago by Dr. Rhea Mehta, Dr. Francisco Diaz-Mitoma, and his son, Francisco Diaz-Mitoma Jr. Combining forces with robotics engineer Saúl Ibaven Bueno, the team is led by frontrunners in their respective industries, with the credentials and experience to bring Bowhead Health from concept through to a revolutionary medical device.
Besides its impressive leadership team, the company has received an undisclosed amount of investment from Grupo Arcoiris, a design and manufacturing firm with over 600 employees, that counts Bayer, Sanofi Pasteur, Merck, Pfizer among its clients.
“Bowhead Health is at the bleeding edge of science and we are proud to join forces to accomplish a technical feat,” says David Bueno, Chief Operating Officer at Grupo Arcoiris.
Funds from the Bowhead token sale will be used to fund research, development, and manufacturing of the medical device and Bowhead platform. As the Bowhead community grows, the influx of customer data will greatly improve the user recommendation algorithm, benefiting customers with more targeted nutritional supplements and medicine.
